Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Share Option Schemes

15 Feb 2012 07:00

RNS Number : 4324X
Imaginatik PLC
15 February 2012
 



15 February 2012

Imaginatik plc

("Imaginatik" or the "Company")

 

Share Option Schemes

 

Imaginatik plc (AIM: IMTK), a leading provider of enterprise innovation services including a range of technology products and consultancy, announces that the remuneration committee of the Board has approved changes to the terms of the existing share options issued by the Company.

 

There are currently 27,461,845 options outstanding under the Company's various share option schemes, of which 24,012,500 are held by directors and eligible employees. 12,006,250 of these options have now been cancelled and the exercise price of a further 12,006,250 options, which currently ranges from 2.0p to 2.55p, has been rebased to 1p per share. The mid-market price of the Company's ordinary shares as at close of business on 14 February 2012 was 0.42p.

 

In addition, the Company has awarded 64,425,000 new share options to directors and employees with an exercise price of 1p per share ("New Options"):

 

a. Matt Cooper, Shawn Taylor, Luis Solis and Nicholas Goss, each being an executive director of the Company, have been granted 17,500,000, 11,125,000, 7,500,000 and 5,000,000 options respectively. The grant of a higher number of options to Mr Cooper and Mr Taylor is in recognition of salary sacrifices on their part during the half-year to 30 September 2011. The share options for Mr Cooper and Mr Taylor will be a combination of options issued under The Imaginatik plc Enterprise Management Incentive Scheme ("EMI scheme") as well as unapproved options. The share options for Mr Goss will all be issued under the EMI scheme. The share options for Mr Solis shall be issued under the Imaginatik 2006 Stock Option Plan.

 

b. David Gammon, Simon Charles and Brian Hays, non-executive directors of the Company, have each been granted 2,000,000 share options. The share options for Mr Gammon and Mr Charles shall be issued as unapproved options, and those for Mr Hays shall be issued under the Imaginatik 2006 Stock Option Plan.

 

c. Key employees of the Company have been granted 17,300,000 share options under the EMI scheme as well as the Imaginatik 2006 Stock Option Plan.

 

The re-based options and the New Options will vest as to 50% two years after grant and 50% three years after grant, subject to certain events as particularised in the scheme rules.

 

The remuneration committee considers that the grant of the New Options and the combined re-basing and cancellation of existing options provides the senior management team and employees of the Company with an appropriate and effective incentive for the future.

 

In addition to the above grants, Northland Capital Partners Limited has been granted 3,206,451 options over new ordinary shares exercisable at any time at 0.5p per share expiring on 13 February 2017 (in connection with the recent placing and open offer).

 

Imaginatik now has 78,087,046 share options in issue, representing approximately 15.22% of the current issued share capital and 13.21% of the fully diluted share capital.

 

Executive Directors

Options

Matt Cooper

19,062,500

Shawn Taylor

14,225,000

Luis Solis

9,500,000

Nicholas Goss

5,000,000

Non-Executive Directors

David Gammon

2,000,000

Simon Charles

2,000,000

Brian Hays

2,000,000

Employees

17,643,750

Ex-employees

3,449,345

Northland Capital Partners

3,206,451

 

 

 

Matt Cooper, Shawn Taylor and Luis Solis, Executive Directors of the Company and Mr Andrew Wainwright, a former Executive Director of the Company, are participating in the re-basing of the existing share options to the extent of an aggregate of 8,537,500 options. The re-basing of the share options is deemed to be a related party transaction under the AIM Rules for Companies. Nicholas Goss, Brian Hays and David Gammon, the independent directors of the Company for the purposes of the transaction, having consulted with the Company's Nominated Adviser, Northland Capital Partners Limited, consider that the terms of the re-basing of the existing share options are fair and reasonable so far as the shareholders of the Company are concerned.

 

Matt Cooper, Executive Chairman of Imaginatik, commented, "Following a comprehensive review of the Company's share option schemes, we are pleased to have put in place a revised share option structure that we believe properly incentivises our employees to build the Company in the long term."

 

For further information please contact:

 

Imaginatik plc

Tel: 020 7917 2975

Matt Cooper, Executive Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited

Tel: 020 7796 8800

Gavin Burnell / Edward Hutton

Newgate Threadneedle

Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

 

About Imaginatik

 

Imaginatik provides Innovation and Idea management solutions comprised of consultancy, software and program management to deliver innovation outcomes to companies such as The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. This is Imaginatik's area of expertise.

 

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and a World Economic Forum Technology Pioneer with offices in Boston, MA, and London. In 2009, Imaginatik was named as one of the 500 fastest growing technology companies in the EMEA region by Deloitte. For more information, visit www.imaginatik.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFVTFRISLIF
Date   Source Headline
19th Dec 20083:16 pmRNSDirector/PDMR Shareholding
18th Dec 20089:45 amRNSDirector/PDMR Shareholding
17th Dec 20087:00 amRNSShare Option Schemes
1st Dec 20087:00 amRNSDirector's Disclosure Update
19th Nov 200812:39 pmRNSDirectors Dealing
13th Nov 20087:00 amRNSInterim Results
14th Oct 20087:00 amRNSTrading Statement
2nd Oct 20087:00 amRNSContract Win
30th Sep 20084:30 pmRNSTotal Voting Rights
24th Sep 20087:00 amRNSDirector/PDMR Shareholding
15th Sep 20087:00 amRNSContract Win
3rd Sep 20087:00 amRNSIssue of Equity
21st Aug 20087:00 amRNSContract Win
28th Jul 20089:27 amRNSNon-Executive Retirement
10th Jul 200810:20 amRNSResult of AGM
10th Jul 20087:00 amRNSAGM Statement
24th Jun 20087:00 amRNSDirector/PDMR Shareholding
18th Jun 200810:05 amRNSAnnual Report and Accounts
13th Jun 200812:16 pmRNSDirector/PDMR Shareholding
11th Jun 20087:00 amRNSFinal Results
1st Apr 200811:52 amRNSDirector Dealings
31st Mar 20084:30 pmRNSTotal Voting Rights
17th Mar 20082:57 pmRNSShare Subscription - Update
10th Mar 20082:23 pmRNSShare Subscription
10th Mar 20089:30 amRNSHolding(s) in Company
28th Feb 200810:01 amRNSPfizer Update
13th Feb 20089:40 amRNSTrading Statement
22nd Jan 20089:30 amRNSWorld Economic Forum
11th Jan 200810:13 amRNSMajor Contract Wins
30th Nov 20072:41 pmRNSWEF Technology Pioneer
14th Nov 20072:12 pmRNSInterim Results
16th Aug 200711:05 amRNSAgreement With IBM
14th Aug 20074:55 pmRNSAIM Rule 26 Information
27th Jul 200710:46 amRNSAGM Statement
27th Jul 20077:01 amRNSAGM Statement
11th Jul 200712:00 pmBUSGlobal Competition Forces Innovation and Collaboration Acceleration
29th Jun 20073:33 pmRNSAnnual Report and Accounts
13th Jun 200711:50 amRNSResult of EGM
12th Jun 20077:02 amRNSFinal Results
4th Jun 20077:02 amRNSUK & European Contract Wins
1st Jun 200710:29 amRNSNotice of Results
18th May 200710:05 amRNSNotice of EGM
23rd Apr 20072:38 pmBUSImaginatik Wins a Queens Award for Enterprise
23rd Apr 200711:02 amRNSWins A Queens Award
19th Apr 200710:59 amRNSDirector/PDMR Shareholding
21st Mar 20077:04 amRNSSenior Management Appointment
21st Mar 20077:01 amBUSImaginatik Appoints President, Americas and New CMO to Accommodate Growth
16th Mar 200711:45 amRNSTrading Statement
9th Feb 200711:30 amBUSImaginatik Appoints Managing Director in United Kingdom
9th Feb 20077:00 amRNSAppointment of UK MD

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.